Figure 1 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

figure

posted on 2025-01-29, 10:00 authored by Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R. Mirza, Bradley J. Monk, Ignace Vergote, Bhavana Pothuri, Whitney A. Spannuth Graybill, Carsten Goessel, Olena Barbash, Giovanna Bergamini, Bin Feng

Retrospective analysis of PRIMA clinical trial–the interaction between niraparib and statin is significant. A, Kaplan–Meier estimation of PFS comparing patients treated with niraparib (n = 92) and placebo (n = 51) in the cohort with statin concomitant; stratified analysis with three randomization factors (response to first platinum, HRd status, and neoadjuvant usage); mPFS, HR, and log-rank test P value are reported. B, Kaplan–Meier estimation of PFS comparing patients treated with niraparib (n = 392) and placebo (n = 193) in the cohort without statin concomitant. C, Kaplan–Meier estimation of PFS comparing all four arms (the placebo without statins was the reference arm for comparison to the other three arms: niraparib, niraparib + statin, and placebo + statin). Statin and niraparib showed the synergistic combination effect (significant interaction) in this retrospective analysis. No significant differences in baseline characteristics (e.g., age and weight) across groups were observed (Supplementary Table S3). D, Kaplan–Meier estimation of PFS comparing niraparib to niraparib + statin arm.

History

ARTICLE ABSTRACT

The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.